Skip to main content

Table 3 Results of responsiveness testing for FACT-8D and EQ-5D-5L using data from baseline to 31 weeks

From: Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

 

FACT-8D

EQ-5D-5L Crosswalk

EQ-5D-5L EVS

Mean change

P

ES

Mean change

P

ES

Mean change

P

ES

FACT-Lym Total (6.5 point MID) [23]

 

< 0.0001

  

<.0001

  

<.0001

 

 Improve (N = 51) a

0.17

 

0.94

0.10

 

0.66

0.09

 

0.64

 No change (N = 36)

0.01

  

−0.01

  

−0.01

  

 Worsen (N = 33)

−0.121

 

0.67

−0.11

 

0.73

−0.11

 

0.79

LymS

(5 point MID) [24]

 

< 0.0001

  

<.0001

  

<.0001

 

 Improve (N = 46)

0.16

 

0.76

0.12

 

0.75

0.10

 

0.67

 No change (N = 58)

−0.0002

  

−0.04

  

−0.04

  

 Worsen (N = 16)

−0.16

 

0.76

−0.12

 

0.75

−0.12

 

0.8

ECOG status

 

0.63

 

0.19

 

0.14

 Improve (N = 26)

0.03

  

0.02

  

0.00

  

 No change (N = 82)

0.05

  

−0.02

  

0.02

  

 Worsen (N = 13)

−0.01

  

−0.07

  

−0.08

  

HgB, </> 120 (women) or 130 g/L (men) [22]

 

0.002

  

0.02

  

0.005

 

 Improve (N = 15)

0.18

 

0.86

0.13

 

0.76

0.12

 

0.75

 No change (N = 76)

0.05

  

0.01

  

0.00

  

 Worsen (N = 30)

−0.05

 

0.24

−0.03

 

0.18

−0.04

 

0.25

  1. ECOG Eastern Cooperative Oncology Group, ES Effect size, EVS England value set, HgB Haemoglobin, LymS FACT-Lym lymphoma specific additional concerns subscale. aThe number of patients showing improvement/worsening/no change corresponds to the total number of patients still in the trial at Week 31 with available changes from baseline on each of the characteristics analysed